A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors (Q36087894)

12 August 2017

A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors (English)

1 reference

12 August 2017

phase I clinical trial

0 references

5

George Wilding

1 reference

12 August 2017

Kyle Holen

1

1 reference

12 August 2017

Robert DiPaola

2

1 reference

12 August 2017

Glenn Liu

3

1 reference

12 August 2017

Antoinette R Tan

4

1 reference

12 August 2017

Karl Hsu

6

1 reference

12 August 2017

Nancy Agrawal

7

1 reference

12 August 2017

Cong Chen

8

1 reference

12 August 2017

Lingling Xue

9

1 reference

12 August 2017

Elizabeth Rosenberg

10

1 reference

12 August 2017

Mark Stein

11

1 reference

12 August 2017

22 March 2011

1 reference

Investigational New Drugs

12 August 2017

1 reference

12 August 2017

30

1 reference

12 August 2017

3

1 reference

12 August 2017

1088-1095

1 reference

A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

Microtubule dynamics as a target in oncology

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

Microtubule active agents: beyond the taxane frontier

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

Progress on kinesin spindle protein inhibitors as anti-cancer agents

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

Review: tubulin function, action of antitubulin drugs, and new drug development

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

Antitumor activity of a kinesin inhibitor

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

Mechanism of taxane neurotoxicity

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394096

Accelerated titration designs for phase I clinical trials in oncology

2 October 2017

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21424701

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-011-9653-1

1 reference

release_zhbh2breozfdvje5estzexnoo4

12 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zhbh2breozfdvje5estzexnoo4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

12 August 2017

PubMed publication ID

21424701

1 reference